


# Cell Chemical Biology

## Copper-Binding Small Molecule Induces Oxidative Stress and Cell-Cycle Arrest in Glioblastoma-Patient-Derived Cells

### Graphical Abstract



### Authors

Kenichi Shimada, Eduard Reznik, Michael E. Stokes, ..., Ana C. deCarvalho, Donald C. Lo, Brent R. Stockwell

### Correspondence

bstockwell@columbia.edu

### In Brief

Shimada et al. report that the compound NSC319726 arrests glioblastoma-patient-derived cells at picomolar concentrations. The compound binds to copper, generates ROS using ambient oxygen, and depletes nucleotide pools. This represents a new strategy for potentially blocking the growth of glioblastoma.

### Highlights

- Picomolar NSC319726 arrests growth of glioblastoma-patient-derived cells
- NSC319726 binds to copper to induce oxidative stress using ambient oxygen
- NSC319726-derived ROS target purine deoxyribonucleosides to arrest cell cycle

# Copper-Binding Small Molecule Induces Oxidative Stress and Cell-Cycle Arrest in Glioblastoma-Patient-Derived Cells

Kenichi Shimada,<sup>1,8</sup> Eduard Reznik,<sup>1</sup> Michael E. Stokes,<sup>1</sup> Lakshmi Krishnamoorthy,<sup>3</sup> Pieter H. Bos,<sup>1</sup> Yuyu Song,<sup>7</sup> Christine E. Quartararo,<sup>1</sup> Nen C. Pagano,<sup>1</sup> Darren R. Carpizo,<sup>4</sup> Ana C. deCarvalho,<sup>5</sup> Donald C. Lo,<sup>6</sup> and Brent R. Stockwell<sup>1,2,9,\*</sup>

<sup>1</sup>Department of Biological Sciences, Columbia University, New York, NY 10027, USA

<sup>2</sup>Department of Chemistry, Columbia University, New York, NY 10027, USA

<sup>3</sup>Howard Hughes Medical Institute, Department of Chemistry, University of California, Berkeley, CA 94720, USA

<sup>4</sup>Rutgers Cancer Institute of New Jersey, New Brunswick, NJ 08903, USA

<sup>5</sup>Department of Neurosurgery, Henry Ford Hospital, Detroit, MI 48202, USA

<sup>6</sup>Center for Drug Discovery and Department of Neurobiology, Duke University Medical Center, Durham, NC 27710, USA

<sup>7</sup>Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA 02115, USA

<sup>8</sup>Present address: Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA 02115, USA

<sup>9</sup>Lead Contact

\*Correspondence: [bstockwell@columbia.edu](mailto:bstockwell@columbia.edu)

<https://doi.org/10.1016/j.chembiol.2018.02.010>

## SUMMARY

Transition metals are essential, but deregulation of their metabolism causes toxicity. Here, we report that the compound NSC319726 binds copper to induce oxidative stress and arrest glioblastoma-patient-derived cells at picomolar concentrations. Pharmacogenomic analysis suggested that NSC319726 and 65 other structural analogs exhibit lethality through metal binding. Although NSC319726 has been reported to function as a zinc ionophore, we report here that this compound binds to copper to arrest cell growth. We generated and validated pharmacogenomic predictions: copper toxicity was substantially inhibited by hypoxia, through an hypoxia-inducible-factor-1 $\alpha$ -dependent pathway; copper-bound NSC319726 induced the generation of reactive oxygen species and depletion of deoxyribosyl purines, resulting in cell-cycle arrest. These results suggest that metal-induced DNA damage may be a consequence of exposure to some xenobiotics, therapeutic agents, as well as other causes of copper dysregulation, and reveal a potent mechanism for targeting glioblastomas.

## INTRODUCTION

Transition metals play essential and diverse roles in cell biology (Dudev and Lim, 2008; Waldron and Robinson, 2009; Williams, 2014). Redox-inactive metals, such as sodium and potassium, signal by changing their distributions quickly, while redox-active metals, such as iron embedded within protein active sites, act as co-factors to aid in catalytic functions (Chang, 2015). Despite their critical role, excess abundance of transition metals can be

toxic to cells. As a result, cellular abundance of transition metals is tightly regulated. Copper is the third most abundant transition metal in biological systems, after iron and zinc. Copper is a redox-active metal like iron, and this property is exploited by enzymes, such as cytochrome c oxidase, superoxide dismutase, and tyrosinase, which participate in many biological processes (Malmström and Leckner, 1998; Solomon et al., 1992). Copper also controls lipolysis in adipocytes by regulating the activity of cAMP-degrading enzyme phosphodiesterase PDE3B (Krishnamoorthy et al., 2016). Also, dysregulation of copper metabolism can cause pathologies. For example, genetic diseases such as Wilson's disease or treatment with some xenobiotic compounds leads to copper accumulation, which causes toxicity, in some cases by triggering oxidative stress (Gaetke and Chow, 2003; Uriu-Adams and Keen, 2005).

In this study, we discovered that the thiosemicarbazone NSC319726 induces copper-dependent cell-cycle arrest at picomolar concentrations in glioblastoma (GBM) cells. Using pharmacogenomic and molecular and cell biology approaches, we found that this compound functions in GBM cells as a copper ionophore. Copper bound to NSC319726 causes the generation of reactive oxygen species (ROS), and induces G1 cell-cycle arrest.

## RESULTS

### NSC319726 Is a Potent Growth Inhibitor of Cancer Cells

GBM is one of the most common and lethal cancers (Dunn et al., 2012). To identify mechanisms for treating this intractable cancer, we performed small-molecule screening in 13 primary-tumor-derived models from GBM patients using stem cell culture conditions in a high-throughput assay format (Quartararo et al., 2015). We discovered that NSC319726 is an extremely potent growth inhibitor, with half maximal effective concentrations ranging from 12 pM to 25 nM across these models (Table 1). NSC319726 induces a cytostatic effect not only in GBM

**Table 1. Sensitivity to NSC319726 and TP53 Mutation Status of Patient-Derived GBM Cells**

GBM Line	EC <sub>50</sub> (nM)	TP53 Mutation
HF3037	0.012	WT
HF2998	0.012	WT
HF2885	0.014	WT
HF2906	0.040	R175H
HF3026	0.042	WT
HF2381	0.046	WT
HF2876	0.095	WT
HF3013	0.130	V272M
HF2476	0.197	WT
HF2303	0.959	G245S
HF3177	1.747	M133T
HF2790	6.791	C242F
HF2941	24.960	WT


EC<sub>50</sub>, half maximal effective concentration; WT, wild-type.

primary-tumor-derived samples, but also in HT-1080 fibrosarcoma cells, albeit at lower potency, indicating a potentially broad spectrum of effectiveness. Since HT-1080 cells grow rapidly and are more amenable to diverse assay formats compared with GBM lines, we initially characterized the mechanism of action of NSC319726 in this cell line. We synthesized the compound, which showed equivalent potency to commercially available batches, confirming the identity of the compound (Figures S1A–S1C).


NSC319726 was originally discovered as a selective lethal compound for cancer cell lines carrying allele-specific TP53 mutation, R175H (Yu et al., 2014; Lin et al., 2015). The gain-of-function R175H mutation is one of the most frequent mutations observed in TP53 gene, contributing to various properties of transformed cancers, such as invasion, proliferation, and drug resistance (Soussi and Wiman, 2007). p53<sup>R175H</sup> protein has decreased binding affinity to Zn<sup>2+</sup>, which is required for DNA binding, resulting in a change in protein conformation (Xu et al., 2011). NSC319726 was reported to function as zinc metallochaperone (and thereby named ZMC1), increasing the intracellular Zn<sup>2+</sup> pool to correct the p53<sup>R175H</sup> protein conformation to that of wild-type p53. It was found that cancers carrying p53<sup>R175H</sup> rely on the “acquired functions” of the mutant protein for their survival, thus NSC319726 kills these addicted cells. Since the binding affinity of p53<sup>R175H</sup> to Zn<sup>2+</sup> is diminished, the mutant protein lacks Zn<sup>2+</sup>, which is required for DNA binding. NSC319726 was shown to facilitate the binding of zinc to p53<sup>R175H</sup> by acting as a zinc ionophore, which enables the mutant protein to recover its wild-type conformation (Yu et al., 2012, 2014).

NSC319726 acts as a zinc metallochaperone in cancers carrying p53<sup>R175H</sup>. Knockdown of TP53 in these cells blocks the compound's efficacy dramatically, strongly indicating the role of correctly folded p53 involved in the mechanism of NSC319726 in these cells. However, other cancer cells carrying wild-type or different mutations of p53 exhibit sensitivity to NSC319726, and the compound's mechanism of action against these cells is not clear. Therefore, we sought to define the mechanism of action of this compound in these contexts.


## A Zn(II) modulation and sensitivity to NSC319726



## B Non-apoptotic cell death inducers structurally similar to NSC319726



## C Co(II) is a NSC319726 suppressor



## Figure 1. NSC319726 Is a Potent Growth Inhibitor of Cancer Cells


(A) The effect of zinc supplementation and chelation on sensitivity to NSC319726.

(B) Structures of NSC319726 and similar previously reported non-apoptotic cell-death inducers.

(C) The effect of 100 μM Co<sup>2+</sup> on NSC319726 toxicity. Error bars in (A and C) indicate SEM of technical triplicates. See also Figures S1A–S1D.

First, we explored the hypothesis that NSC319726 might cause zinc accumulation or interfere with p53 activity in GBM and HT-1080 cells. While Zn<sup>2+</sup> supplementation slightly increased the compound's efficacy in these contexts, treatment with a specific Zn<sup>2+</sup> chelator, *N,N,N',N'*-tetrakis(2-pyridinylmethyl)-1,2-ethanediamine (Verhaegh et al., 1998), did not substantially change its potency or efficacy in HT-1080 cells or GBM models, suggesting that the effect of NSC319726 is largely independent of binding to Zn<sup>2+</sup> in these cell models, while Zn<sup>2+</sup> supplementation slightly potentiated the effect of the compound (Figure 1A). Moreover, we did not observe a connection between TP53 mutation status and the sensitivity to NSC319726 across the 13 GBM models (Table 1). Although the latter analysis was performed with too few cells to conclusively find associations between genotype and phenotype, we were motivated to seek additional mechanisms underlying the cytostatic effect of the compound in these cell types.

## A Gl<sub>50</sub> profile in the NCI-60 panel




## Figure 2. NSC319726, 8-Hydroxyquinoline, and Phenothiazine Share Similar Mechanisms of Action against Cancer Cells

(A) Left: relative growth inhibition (GI<sub>50</sub>) profiles across the NCI-60 panel against 18 compound clusters representing distinct mechanisms of action of 2,565 cell-line-selective lethal compounds. Right: relative GI<sub>50</sub> profiles of 83 compounds in the cluster represented by NSC319726.


(B) Four core scaffolds represented in the same cluster as NSC319726.

(C) Median sensitivity of the 83 compounds across the NCI-60 panel. The red dot indicates NSC319726.

## B Scaffolds clustered with NSC319726



## C Median GI<sub>50</sub> across NCI60 cells



Examination of the structure of NSC319726 revealed that it is similar to three cytotoxic compounds that induce a non-apoptotic form of cell death (Shimada et al., 2016a) (Figure 1B). These compounds were discovered in a screen specifically for lethal molecules that induce regulated, non-apoptotic cell death (Shimada et al., 2016a). Their lethality in cancer cell lines was inhibited by binding to Co<sup>2+</sup>, although their mechanism of action was not fully elucidated. Due to the structural similarity, we suspected that NSC319726 might share a similar mechanism of action. Intriguingly, NSC319726's cytostatic effect was strongly inhibited by supplementation with 100  $\mu$ M Co<sup>2+</sup>, which is similar to the effect observed with these three reported compounds (Figure 1C). Co<sup>2+</sup> is an essential transition metal, widely known for its function in a co-factor vitamin B<sub>12</sub>. However, as holo-B<sub>12</sub> supplementation did not suppress NSC319726's lethality, depletion of Co<sup>2+</sup> from B<sub>12</sub> is likely not the cause of NSC319726's cytotoxic effect (Figure S1D).

## Three Distinct Compound Scaffolds Share Similar Lethal Mechanisms

While NSC319726 exhibited picomolar potency in some GBM-patient-derived models, the difference in potency between the 13 cell lines was >2,000-fold. We previously studied a publicly avail-


able large pharmacogenomic dataset to identify biomarkers predicting drug sensitivity, and reported that lethal compounds whose potency vary across different cells were informative for study of molecular mechanisms (Shimada et al., 2016b).

The NCI-60 dataset contains basal gene expression profiles of 60 cell lines, as well as drug sensitivity for 6,529 compounds (Shoemaker, 2006). Of these, we focused on 2,565 cell line-selective compounds, clustered them into 18 groups based on the similarity of the drug sensitivity across 60 cell lines, and found that each cluster represents distinct mechanisms (e.g., DNA-targeting agents, tyrosine kinase inhibitors, and ferroptosis inducers) (Shimada et al., 2016b). NSC319726 was included in the 2,565 cell-line-selective compounds tested in the NCI-60 dataset, and these analyses

revealed that NSC319726 clustered together with 82 other compounds (Figure 2A). While these 83 compounds were clustered based on the similarity of the sensitivity profile across cell lines, the compounds in this cluster also share substantial structural similarities and are characterized by four core scaffolds (Figure 2B). The first two classes contain a semicarbazone and a heteroatom (either nitrogen or sulfur), suggesting that these scaffolds bind to metal ions. Notably, NSC319726 and three structural analogs are also nitro- or thiosemicarbazones (Figure 2B). As for the latter two classes, 8-hydroxyquinoline compounds are known to form metal complexes (Prachayasittikul et al., 2013), while phenothiazines are not reported to bind to metals. Whether these compounds are capable of binding to metals or not, these 83 compounds were suspected to induce similar lethality compared with the other 2,565 cell line-selective lethal compounds, based on their growth inhibition profiles. Among these, thio-/nitrosemicarbazones were more potent than 8-hydroxyquinolines or phenothiazines, and, notably, NSC319726 was one of the most potent compounds (Figure 2C).

## NSC319726 Induces Copper-Dependent Toxicity

The NCI-60 data analysis suggested that semicarbazones, including NSC319726, bind to metal ions to induce lethality in



**Figure 3. NSC319726 Induces Copper Toxicity**

(A) The effect of various metal supplementation on the sensitivity to NSC319726 was seen in HT-1080 cells.

(B) The effect of  $\text{Cu}^{2+}$  and/or  $\text{Co}^{2+}$  supplementation on HT-1080 cells' sensitivity to NSC319726. Color code is the same as (A). In (A) and (B), testing metals were treated at 2-fold dilution series with 100  $\mu\text{M}$  as highest concentration, while  $\text{Co}^{2+}$  and NSC319726 were co-supplemented at fixed concentrations, 100  $\mu\text{M}$  and 31 nM, respectively.

(C) The effect of  $\text{Cu}^{2+}$  modulation on the sensitivity to NSC319726, 7Br8HQ, and MB.

(D) Intracellular metal quantification upon NSC319726/7Br8HQ/MB treatment.

(E) Intracellular metal quantification upon NSC319726 and/or  $\text{Co}^{2+}$  supplementation.

(F) Time course measurement of copper and zinc for 0, 3, 9, and 24 hr. Values in (D–F) were normalized to inorganic phosphate quantity of the same samples. Error bars in (B and C) are SEM of technical triplicates, (D–F) are SEM of biological triplicates. See also Figure S1E.


cancer cells. We sought to identify the metal species responsible for this effect. Thiosemicarbazones have long been studied as a potential anticancer agent, and their binding to transition metal ions, particularly iron, zinc, and copper, is suggested to be the key for their lethal effect (Crim and Petering, 1967; Sartorelli et al., 1977). To find out if this is the case, we assessed if any specific metal-binding is important for semicarbazones. A cell-permeable metal-binding compound acting as an ionophore decreases the concentration gradient across the plasma membrane. It may deplete or overload the metal, depending on the ratio between its intra- and extracellular concentrations. In either scenario, supplementation of the corresponding metal ion should alter the effect of NSC319726. We co-treated HT-1080 cells with NSC319726 and various metal ions in a concentration series, and found that only  $\text{Cu}^{2+}$  dramatically enhanced the growth inhibitory effect of the compound. This effect of  $\text{Cu}^{2+}$  was diminished by the addition of  $\text{Co}^{2+}$  (Figures 3A and 3B). While  $\text{Fe}^{2+}$  and  $\text{Fe}^{3+}$  supplementation also induced growth inhibition that was inhibited by  $\text{Co}^{2+}$  co-treatment (Figure 3A), and the iron-specific chelator deferoxamine suppressed NSC319726's effect (Figure S1E), the effect of iron supplementation was independent of NSC319726. Moreover, iron supple-

mentation was previously found to be protective against NSC319726 in TOV112D cells, similar to  $\text{Co}^{2+}$  supplementation in HT-1080 cells (Yu et al., 2012). Due to this idiosyncratic effect of iron in different cells, and the compound-independent nature of  $\text{Co}^{2+}$  inhibition of iron toxicity in HT-1080 cells, we concluded that iron toxicity was not the key mechanism of NSC319726 lethality in GBM and HT-1080 cells.

To ensure that NSC319726's interaction with copper was relevant to its lethality, we treated cells with a dilution series of NSC319726 in medium supplemented with either  $\text{Cu}^{2+}$ , in the absence or presence of the  $\text{Cu}^{2+}$ -specific chelator, triethylenetetramine (TETA) (Figure 3C) (Lu, 2010). Consistent with the hypothesis that NSC319726 binds copper to induce its growth inhibitory effect, the copper chelator reversed the synergy between  $\text{Cu}^{2+}$  and NSC319726. Two other compounds were tested in similar conditions: 7-bromo-8-hydroxyquinoline (7Br8HQ) and methylene blue (MB), representing the 8-hydroxyquinoline and phenothiazine scaffolds, respectively. 7Br8HQ was potentiated by  $\text{Cu}^{2+}$  and unchanged by TETA; MB was unchanged by either (Figure 3C).

To evaluate the relationship between these three compounds and the cellular accumulation of metals, we directly measured the abundance of iron, copper, and zinc in HT-1080 cells using inductively coupled plasma mass spectrometry. Consistent with previous and earlier findings,  $\text{Cu}^{2+}$  and  $\text{Zn}^{2+}$  were significantly increased upon treatment with either NSC319726 or 7Br8HQ, whereas treatment with MB had no effect. Moreover, NSC319726 specifically increased cellular copper abundance, while 7Br8HQ increased the level of all three metal ions. Taken together, these findings indicate that NSC319726 can function





**Figure 4. HIF-1 $\alpha$ -Dependent Response to Hypoxia Induces Resistance to NSC319726**

(A) Summary of the pathway enrichment analysis. (B) Effect of hypoxia on NSC319726-induced lethality. Error bars are SEM from sigmoidal curve fitting of a representative experiment. (C) Effect of siHIF-1 $\alpha$  on HIF-1 $\alpha$  protein level (left) and cellular sensitivity to NSC319726. (D) Chemical induction of HIF-1 $\alpha$  and cellular sensitivity to NSC319726. (E) Schematic relationship between NSC319726 and hypoxia. Error bars in (C and D) indicate SEM of technical triplicates. See also Figures S2 and S3.

as a specific copper and zinc ionophore, that 7Br8HQ is a non-specific transition metal ionophore, and that MB is not a metal chelator (Figure 3D). The increase in copper and zinc abundance was suppressed by the addition of Co<sup>2+</sup>, suggesting that NSC319726 binds to Co<sup>2+</sup> when the latter is present in excess (Figure 3E). Copper levels significantly increased as quickly as 3 hr after NSC319726 treatment, and steadily increased up to 24 hr post treatment (Figure 3F).

The metal quantification and cell viability assays after perturbation of metal content suggest a couple of important features: NSC319726 specifically binds to both copper and zinc, of which copper is specifically responsible for NSC319726's cytotoxicity; 7Br8HQ binds to several transition metals; the effect of MB is independent of copper. Second, NSC319726 inhibited cell growth and killed cells completely when Cu<sup>2+</sup> was further added to the cell culture, while 7Br8HQ induced complete lethality without copper supplementation. This discrepancy is possibly

due to the difference in metal binding specificity of the two molecules. Metals that 7Br8HQ binds to but NSC319726 does not, such as iron, may induce complete lethality achieved by 7Br8HQ. Thus, 7Br8HQ seems to induce two mechanisms of lethality: a copper-dependent mechanism that is comparable with NSC319726's toxicity and a copper-independent mechanism that is orthogonal to NSC319726's toxicity.


### Transcriptome Analysis Uncovered Gene Signatures of Sensitivity and Resistance to NSC319726

In a prior NCI-60 analysis, we found that drug sensitivity profiles are indicative of mechanisms of action, and that the transcriptome can be used to successfully discover biomarkers of sensitivity (Shimada et al., 2016b). Using the same approach, we looked for pathways (entries in Gene Ontology, Kyoto Encyclopedia of Genes and Genomes, Reactome, BioCarta, and "hallmarks" in the Molecular Signatures Database [MSigDB] [Subramanian et al., 2005]) that serve as biomarkers for the sensitivity of cells to compounds in the cluster containing NSC319726 (Figure S2A). We discovered pathways that are significantly upregulated in cell lines sensitive or resistant to this cluster (high significance, corresponding to the x axis of Figure S2B), which are also uniquely associated with this cluster among the 18 clusters shown in Figure 2A (high specificity, corresponding to y axis of Figure S2B).

We then measured gene expression changes after 24 hr of 10  $\mu$ M NSC319726 treatment in the most sensitive (HF3037) and resistant (HF2941) GBM-patient-derived cell models. We asked if any of the pathways with high significance and high specificity in the NCI-60 dataset were up- or downregulated in a meaningful way. We assumed that if genes in a pathway overexpressed in NSC319726-resistant versus sensitive cells in the NCI-60 dataset were also up- or downregulated in resistant GBM cells (HF2941) than sensitive ones (HF3037) in the basal state in both the NCI-60 and the GBM cell panels, but they were also even more expressed upon NSC319726 treatment in the two GBM cells; thus, we suspected that these pathways were functionally relevant to the mechanism that cells use to acquire resistance to NSC319726. We then evaluated how hypoxia might contribute to resistance further.

### Hypoxia Suppresses NSC319726 through an HIF-1 $\alpha$ -Dependent Pathway

We first tested whether hypoxia made cells resistant to NSC319726 in four GBM models. Cells grown in hypoxia (1.5% O<sub>2</sub>) were more resistant to NSC319726 than cells grown in normoxia (ambient, 21% O<sub>2</sub>) by 100-fold in all four cell models tested (Figures 4B and S3A). As the transcriptional response to hypoxia is regulated in part by hypoxia-inducible factor 1 $\alpha$  (HIF-1 $\alpha$ ), encoded by *HIF1A* gene, and copper can stabilize HIF-1 $\alpha$  by inhibiting its prolyl hydroxylation and subsequent degradation (Martin et al., 2005), we suspected that HIF-1 $\alpha$  stabilization might provide a cellular defense mechanism to



**Figure 5. NSC319726 Induces ROS Generation**

(A) ROS measurement using CM-H<sub>2</sub>DCFDA upon NSC319726 and/or Cu<sup>2+</sup> treatment.

(B) The effect of N-acetylcysteine (NAC) supplementation on the lethality of NSC319726.

(C) Abundance of 2'-deoxyguanosine upon NSC319726 and/or Co<sup>2+</sup> supplementation.

(D) Cell-cycle analysis using Nuclear ID Red staining upon treatment of NSC319726/7Br8HQ/MB. Error bars in (B) indicate SEM of technical triplicates. See also [Figures S4–S7](#).

NSC319726. A potent inhibitor of the NSC319726 lethality, Co<sup>2+</sup>, also stabilizes HIF-1 $\alpha$  by inhibiting the interaction between HIF-1 $\alpha$  and von Hippel-Lindau, an E3 ligase, ubiquitinating and promoting HIF-1 $\alpha$  degradation in response to oxygen, which may also contribute to the resistance ([Yuan et al., 2003](#)). We confirmed that HIF-1 $\alpha$  protein was significantly stabilized upon both NSC319726 and Co<sup>2+</sup> treatment, supporting the hypothesis that HIF-1 $\alpha$  may mediate cellular responses to NSC319726 ([Figure S3B](#)).

To explore more directly the role of HIF-1 $\alpha$  in response to NSC319726, HIF-1 $\alpha$  expression was inhibited by small interfering RNA knockdown in HT-1080 cells. Inhibition of HIF-1 $\alpha$  expression restored sensitivity to NSC319726 under hypoxic conditions, explaining the resistance previously observed ([Figure 4C](#)). However, HIF-1 $\alpha$ -mediated resistance was achieved only in hypoxic conditions, because HIF-1 $\alpha$  knockdown marginally sensitizes cells to NSC319726 in normoxic conditions, and treatment with dimethylxallylglycine, a compound that stabilizes HIF-1 $\alpha$  in normoxic conditions, did not alter NSC319726 sensitivity under normoxia ([Figures 4D and S3B](#)). These results indicate that the extent of the stimuli that NSC319726 triggers, leading to cytostasis, varies between hypoxia and normoxia; although HIF-1 $\alpha$  tries to protect cells from NSC319726, the lethal stimuli under normoxia are greater than stabilized HIF-1 $\alpha$  can handle ([Figure 4E](#)).


### NSC319726 Induces ROS Leading to Cell-Cycle Arrest

To further explore what causes cytostasis upstream of HIF-1 $\alpha$  upon NSC319726 treatment, we re-analyzed gene expression changes in two GBM cell models treated with 10  $\mu$ M NSC319726. By comparing their expression profiles with those from 1,698 experiments from chemical and genetic perturbations collected in the MSigDB, we found that NSC319726 treatment of HF3037 and HF2941 GBM cell models induced gene expression profiles similar to T24 bladder cancer cells treated with hypericin-mediated photodynamic therapy ([Figure S4](#)) ([Buytaert et al., 2008](#)). Photodynamic therapy is chemotherapy consisting of the administration of photosensitizing chemicals such as hypericin. The photosensitizing compounds, preferentially taken up by cancers, absorb near infrared light and transfer their energy to oxygen molecules, generating singlet oxygen, which kills cells ([Karioti and Bilia, 2010](#)).

Based on the similar transcriptome profiles, we hypothesized that NSC319726 generates ROS, comparable with photodynamic therapy. Semicarbazones were previously reported to bind to and activate copper, facilitating redox cycling between Cu<sup>+</sup> and Cu<sup>2+</sup>, leading to more efficient ROS generation ([Jansson et al., 2010](#)); we suspected that NSC319726-bound copper was more susceptible to redox changes. Notably, NSC319726-bound copper propagated ROS from hydrogen peroxide in a cell-free solution more efficiently than the free unbound form ([Figures 5A and S5A](#)), supporting this hypothesis.

To determine which ROS are involved in this cytotoxicity, cells were treated with both NSC319726 and one of several antioxidants quenching different ROS; we found that N-acetylcysteine rescued cells at 50 mM. While N-acetylcysteine is not a very specific scavenger, other antioxidants (100  $\mu$ M trolox for lipophilic ROS, and 100  $\mu$ M 4-hydroxy-TEMPO for superoxide) showed little effect on NSC319726 lethality, indicating that lipophilic hydroxyl radicals and superoxide were likely not involved ([Figures S5B and S5C](#)). Moreover, a pan-caspase inhibitor, zVAD, or a necroptosis inhibitor, Necrostatin-1, did not suppress the cytotoxic effect of NSC319726, indicating that known regulated cell death phenotypes, such as apoptosis or necroptosis, were not involved ([Figure S5D](#)). Intriguingly, other scaffolds, 7Br8HQ and MB, also induce ROS generation detectable by CM-H<sub>2</sub>DCFDA, and suppressed by 50 mM N-acetylcysteine ([Figures 5B and S5C–S5E](#)). These shared features suggest that the three compounds evoke ROS-induced cytostasis through a similar mechanism, and explain why these molecules co-segregated in the clustering analysis.

To further understand the implication of NSC319726-mediated ROS production on cellular metabolism, and to glean insight into how these changes could result in cell-cycle arrest, we performed untargeted metabolomic profiling of cells treated with DMSO, NSC319726, DMSO/Co<sup>2+</sup>, and NSC319726/Co<sup>2+</sup> for 6 hr. Across these four conditions, only NSC319726 treatment induced lethality. Among the 505 metabolites identified and quantified, we looked for metabolites whose abundance was changed significantly over the other conditions, and the analysis revealed that purine deoxyribonucleosides/deoxyribonucleotides, namely, 2'-deoxyadenosine and its phosphate



**Figure 6. Model of NSC319726-Induced Toxicity**

Current model of NSC319726's mechanism of action. NSC319726 binds to copper to induce ROS (indicated by a red arrow), possibly singlet oxygen, and arrests cell cycle. While two other scaffolds, 8-hydroxyquinoline and phenothiazine, do not generate ROS through copper binding, they also generate NAC-inhibitable ROS to induce cell-cycle arrest.

conjugates, 2'-deoxyguanosine, and 2'-deoxyinosine, were completely depleted upon NSC319726 treatment (Figures 5C and S6), while pyrimidine deoxyribonucleosides and purine ribonucleosides/ribonucleotides were unaffected. There are two possibilities explaining this observation: first, purine bases were selectively oxidized by NSC319726-copper complex, consistent with prior works showing 8-oxodeoxyguanosine formation upon NSC319726 treatment (Angelé-Martínez et al., 2014; Yu et al., 2014). However, this cannot explain why deoxyribosyl-purines were only depleted while ribosyl-purines were intact. The second possibility is that ribonucleotide reductase (RNR) activity is inhibited by NSC319726. RNR is an enzyme catalyzing the formation of deoxyribonucleotides from ribonucleotides. Triapine, a thiosemicarbazone, was reported to inhibit RNR activity (Finch et al., 2000). Whatever the mechanisms of deoxyribosyl-purine depletion may be, we found G1 cell-cycle arrest in HT-1080 cells 24 hr after NSC319726 treatment. As expected from NCI-60 analysis, 7Br8HQ and MB treatments also induced G1-arrest in HT-1080 cells after 24 hr (Figure 5D), possibly induced by the same ROS as generated by NSC319726 treatment.

### NSC319726 Does Not Exhibit Neurotoxicity in Differentiated SH-SY5Y Cells

One major concern toward clinical application for GBM treatment is neurotoxicity. Thus, we utilized a SH-SY5Y human neuroblastoma cell model to assess the neurotoxicity of NSC319726 (Figure S7). Undifferentiated SH-SY5Y cells were more sensitive to all four lethal compounds with distinct mechanisms compared with the differentiated cells. Among them, a non-specific kinase inhibitor staurosporine was only 4-fold selective between undifferentiated and differentiated cells, but DNA damaging agents, i.e., NSC319726 and type II topoisomerase inhibitor doxorubicin, were much more selective, and differentiated cells did not show substantial toxicity up to the highest tested concentrations. Selective lethality in GBM and neuroblastoma over differentiated and non-growing neurons is a desired characteristic of NSC319726 for an anti-GBM agent.

## DISCUSSION

Although thiosemicarbazones have been long recognized as metal binding molecules and potential anticancer agents, their mechanism of action is complicated because abundant transition metals in cells, i.e., iron, zinc, and copper, seem all relevant in their mechanisms. However, the fact that various thiosemicarbazones showed similar drug sensitivity profiles in a NCI-60 cell line panel indicates that their mechanism of action is similar overall. In this study, we focused on characterizing the mechanism of action of one of the most potent, NSC319726. NSC319726 functions as a copper ionophore that generates ROS to deplete deoxyribosyl-purines and induce growth inhibition in multiple cancer cell models (Figure 6).

To identify molecular pathways involved in NSC319726's lethality, we adopted a pharmacogenomic approach. While large pharmacogenomic efforts such as the NCI-60 project are often considered noisy and inconsistent, we previously showed that proper filtering of the data provides useful signals (Shimada et al., 2016b). In this study, we illustrated how such data can characterize the mechanism of action of a lethal compound. Combining the NCI-60 data with RNA sequencing experiments to detect gene expression changes upon NSC319726 treatment, we identified biomarkers of sensitivity, which are upregulated. This approach can serve to identify gene sets that are not only biomarkers, but functionally relevant to mechanisms of action. Our discovery of HIF-1 $\alpha$  making cells resistant to thiosemicarbazone-induced cytotoxicity has not been reported before; however, structurally related bis(thiosemicarbazone) complexed with Cu<sup>2+</sup> was reported to be accumulated in hypoxic regions *in vivo* and thus is exploited as a hypoxia imaging agent (Price et al., 2011). Notably, its hypoxia-selective biodistribution is highly correlated with the Cu<sup>2+</sup>/Cu<sup>+</sup> redox potential (Dearling et al., 2002). Susceptibility to switch between Cu<sup>+</sup> and Cu<sup>2+</sup> is also the key for toxicity of thiosemicarbazone-copper complex, suggesting that these two phenomena are related. Since a potential anticancer activity of bis(thiosemicarbazone) has also been suggested (Palanimuthu et al., 2013), hypoxic cells should be tolerant to both scaffolds assuming that the toxic mechanism of thiosemicarbazone and bis(thiosemicarbazone) is similar. On the other hand, normoxic cells are more susceptible to thiosemicarbazone-induced cytotoxicity, while they may excrete bis(thiosemicarbazone) from cells more efficiently and achieve hypoxia-selective accumulation of the compound.

To fully connect how the NSC319726-copper complex induces cytostatic effect, the identification of the precise ROS species generated upon NSC319726-copper treatment targeting purine deoxyribonucleosides is required. We also want to note that, although NSC319726-bound Cu<sup>2+</sup> is susceptible to propagate free radicals from hydrogen peroxide more efficiently than unbound Cu<sup>2+</sup> (Figure S5A), hydroxyl radicals may not be the same ROS generated *in vivo*. In regard to the exact ROS, it is tempting to propose that singlet oxygen is generated in response to any of the three compounds (NSC319726, 7Br8HQ, and MB). However, unlike photodynamic therapy, the source of energy to generate singlet oxygen for this mechanism is unknown. There has been evidence reported that small-molecule-bound copper behaves differently to target DNA, possibly



through generation of singlet oxygen (Devasagayam et al., 1991; Frelon et al., 2003; Jose et al., 2011; Li and Trush, 1993; Macomber et al., 2007). We also have evidence supporting the hypothesis that NSC319726-copper complex induces singlet oxygen: (1) transcriptome analysis against the MSigDB revealed that the genes up- and downregulated upon NSC319726 treatment were most significantly correlated with that in hypericin-mediated photodynamic therapy, which induces singlet oxygen (Figure 4C); (2) among multiple ROS scavengers, specific antioxidants targeting hydroxyl radicals, lipid peroxides, and superoxide were not effective, but only N-acetylcysteine suppressed NSC319726 cytotoxicity, but only at higher concentrations; (3) lethal stimuli generated upon NSC319726 treatment are oxygen pressure dependent, suggesting that oxygen molecules may directly contribute to ROS production; and (4) 2'-deoxyguanosine is a known target of singlet oxygen (Jose et al., 2011; Li and Trush, 1993; Ravanat and Cadet, 1995). While these multiple lines of evidence point toward singlet oxygen, in the absence of a plausible mechanism for the generation of singlet oxygen, this remains speculative.

However, and whatever ROS may be generated upon NSC319726 treatment, its picomolar potency to sensitive GBM cells is a valuable property. Toward clinical application, it may be noteworthy that NSC319726's effectiveness may depend on the sex of the patients. Although our analysis based on 13 patient-derived GBM models was not powered for this analysis (p value of 0.073 using Wilcoxon's rank-sum test), NSC319726 was more effective against GBM cells from female patients than GBM cells from male patients (Experimental Model and Subject Details describes the genders of the patients). While there are still certain obstacles to translating this finding into a therapeutic agent, e.g., it was unclear whether NSC319726 penetrates the blood-brain barrier, and what the oxygen tension is in various GBM tissues, a sophisticated drug delivery system to selectively administer drugs to GBM cells along with oxygen might overcome such issues. Irrespectively, these findings suggest that copper dysregulation can induce oxidative stress and DNA damage, leading to cell-cycle arrest. This may have applications in a variety of pathological and therapeutic contexts.

## SIGNIFICANCE

**Transition metals are essential for many cellular functions; deregulation of their metabolism causes toxicity that may be exploited for therapeutic gain. In this study, we report that the compound NSC319726 binds copper to induce oxidative stress and arrest glioblastoma (GBM)-patient-derived cells at picomolar to nanomolar concentrations. This effect was discovered through screening compounds in 13 patient-derived GBM cell models. While NSC319726 has been reported to function as a zinc ionophore at micromolar concentrations in some cancer cell lines, we found that it was not responsible for NSC319726's cytotoxicity to GBM cells. Therefore, we decided to adopt a data-driven pharmacogenomic approach to identify likely mechanism of action of NSC319726; through analysis of drug sensitivity data and basal transcriptome of the NCI-60 human cancer cell line panel, we hypothesized that NSC319726**

**and 65 other structural analogs exhibit lethality through metal binding, consistent with their chemical structures and reported activities. Supplementing with multiple metal ions, we found that NSC319726 binds copper to arrest cell growth in GBM cells. Furthermore, pharmacogenomic analysis of both the NCI-60 data and transcriptomic changes of GBM cells upon NSC319726 treatment suggested that the copper toxicity induced by NSC319726 was substantially inhibited by hypoxia, through an HIF-1 $\alpha$ -dependent pathway; we confirmed this hypoxia-dependent lethality in GBM patient samples using a hypoxia chamber. Treatment with copper-bound NSC319726 resulted in the generation of reactive oxygen species and a depletion of deoxyribosyl-purines, including 2'-deoxyguanosine, resulting in G1 cell-cycle arrest. These data suggest that DNA damage is the primary consequence of copper-mediated oxidative stress, subsequently inducing cell-cycle arrest. Thus, copper dysregulation and metal-induced DNA damage may be a consequence of exposure to some therapeutic agents or xenobiotics. Moreover, this study highlights the power of a data-driven pharmacogenomic approach to characterize mechanism of action of small molecules.**

## STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **CONTACT FOR REAGENT AND RESOURCE SHARING**
- **EXPERIMENTAL MODEL AND SUBJECT DETAILS**
  - Cell Lines and Tissue Culture
- **METHOD DETAILS**
  - Synthesis of NSC319726
  - Cell Viability Assay
  - Sequencing of *TP53* Gene of 13 GBM Primary Cells
  - Screening for Lethal Compounds in 13 GBM Primary Cells
  - Screening for a Responsible Metal in NSC319726-Induced Cell Death
  - Inductively Coupled Plasma-Mass Spectrometry (ICP-MS) for Metal Quantification
  - RNA-Seq Experiment
  - HIF-1 $\alpha$  Knockdown
  - Hypoxia Induction
  - Western Blotting
  - ROS Detection in Cell Culture
  - ROS Detection in Cell Free System
  - Cell Cycle Assay
  - Metabolomic Profiling
  - Neurotoxicity Assays
- **QUANTIFICATION AND STATISTICAL ANALYSIS**
  - Pharmacogenomic Analysis of the NCI-60 Data
  - Processing of Raw Sequences from RNA-Seq
  - Analysis of RNA-Seq Data
  - Pathway Enrichment Analysis
  - Predicting Functionally Relevant Pathways
- **DATA AND SOFTWARE AVAILABILITY**

## SUPPLEMENTAL INFORMATION

Supplemental Information includes seven figures and can be found with this article online at <https://doi.org/10.1016/j.chembiol.2018.02.010>.

## ACKNOWLEDGMENTS

We thank Anna Kaplan of Columbia University, Tom Mikkelsen of Henry Ford Hospital, and Christopher Chang of University of California, and Ray Pagliarini at Novartis Institutes for BioMedical Research, for helpful discussions. This study was supported by funding from the Accelerate Brain Cancer Cure (ABC2) foundation and NIH grants R35CA209896 and P01CA087497 (to B.R.S.). L.K. was supported by NIH grant R01GM079465 and Howard Hughes Medical Institutes.

## AUTHOR CONTRIBUTIONS

Conceptualization, K.S. and B.R.S.; Methodology, K.S., E.R., M.E.S., L.K., P.H.B., Y.S., and C.E.Q.; Software, K.S.; Formal Analysis, K.S.; Investigation, K.S., E.R., M.E.S., L.K., P.H.B., Y.S., C.E.Q., and N.C.P.; Resources, A.C.d.C., P.H.B., and B.R.S.; Data Curation, K.S., E.R., M.E.S., L.K., C.E.Q., and N.C.P.; Writing – Original Draft, K.S. and B.R.S.; Writing – Review & Editing, K.S., M.E.S., L.K., P.H.B., C.E.Q., D.R.C., D.C.L., and B.R.S.; Visualization, K.S.; Supervision, B.R.S.; Project Administration, K.S.; Funding Acquisition, B.R.S.

## DECLARATION OF INTERESTS

The authors declare no conflict of interest.

Received: June 29, 2017

Revised: January 2, 2018

Accepted: February 18, 2018

Published: March 22, 2018

## REFERENCES

- Angelé-Martínez, C., Goodman, C., and Brumaghim, J. (2014). Metal-mediated DNA damage and cell death: mechanisms, detection methods, and cellular consequences. *Metallomics* 6, 1358–1381.
- Buytaert, E., Matroule, J.Y., Durinck, S., Close, P., Kocanova, S., Vandenheede, J.R., de Witte, P.A., Piette, J., and Agostinis, P. (2008). Molecular effectors and modulators of hypericin-mediated cell death in bladder cancer cells. *Oncogene* 27, 1916–1929.
- Chang, C.J. (2015). Searching for harmony in transition-metal signaling. *Nat. Chem. Biol.* 11, 744–747.
- Crim, J.A., and Petering, H.G. (1967). The antitumor activity of Cu(II)KTS, the copper (II) chelate of 3-ethoxy-2-oxobutylaldehyde bis(thiosemicarbazone). *Cancer Res.* 27, 1278–1285.
- Dearling, J.L., Lewis, J.S., Mullen, G.E., Welch, M.J., and Blower, P.J. (2002). Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: structure-activity relationships. *J. Biol. Inorg. Chem.* 7, 249–259.
- Devasagayam, T.P., Steenken, S., Obendorf, M.S., Schulz, W.A., and Sies, H. (1991). Formation of 8-hydroxy(deoxy)guanosine and generation of strand breaks at guanine residues in DNA by singlet oxygen. *Biochemistry* 30, 6283–6289.
- Dixon, S.J., Lemberg, K.M., Lamprecht, M.R., Skouta, R., Zaitsev, E.M., Gleason, C.E., Patel, D.N., Bauer, A.J., Cantley, A.M., Yang, W.S., et al. (2012). Ferroptosis: an iron-dependent form of nonapoptotic cell death. *Cell* 149, 1060–1072.
- Dudev, T., and Lim, C. (2008). Metal binding affinity and selectivity in metalloproteins: insights from computational studies. *Annu. Rev. Biophys.* 37, 97–116.
- Dunn, G.P., Rinne, M.L., Wykosky, J., Genovese, G., Quayle, S.N., Dunn, I.F., Agarwalla, P.K., Chheda, M.G., Campos, B., Wang, A., et al. (2012). Emerging insights into the molecular and cellular basis of glioblastoma. *Genes Dev.* 26, 756–784.
- Finch, R.A., Liu, M., Grill, S.P., Rose, W.C., Loomis, R., Vasquez, K.M., Cheng, Y., and Sartorelli, A.C. (2000). Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone): a potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. *Biochem. Pharmacol.* 59, 983–991.
- Frelon, S., Douki, T., Favier, A., and Cadet, J. (2003). Hydroxyl radical is not the main reactive species involved in the degradation of DNA bases by copper in the presence of hydrogen peroxide. *Chem. Res. Toxicol.* 16, 191–197.
- Gaetke, L.M., and Chow, C.K. (2003). Copper toxicity, oxidative stress, and antioxidant nutrients. *Toxicology* 189, 147–163.
- Hahne, F., LeMeur, N., Brinkman, R.R., Ellis, B., Haaland, P., Sarkar, D., Spidlen, J., Strain, E., and Gentleman, R. (2009). flowCore: a bioconductor package for high throughput flow cytometry. *BMC Bioinformatics* 10, 106.
- Jansson, P.J., Sharpe, P.C., Bernhardt, P.V., and Richardson, D.R. (2010). Novel thiosemicarbazones of the ApT and DpT series and their copper complexes: identification of pronounced redox activity and characterization of their antitumor activity. *J. Med. Chem.* 53, 5759–5769.
- Jose, G.P., Santra, S., Mandal, S.K., and Sengupta, T.K. (2011). Singlet oxygen mediated DNA degradation by copper nanoparticles: potential towards cytotoxic effect on cancer cells. *J. Nanobiotechnology* 9, 9.
- Karioti, A., and Bilia, A.R. (2010). Hypericins as potential leads for new therapeutics. *Int. J. Mol. Sci.* 11, 562–594.
- Klayman, D.L., Bartosevich, J.F., Griffin, T.S., Mason, C.J., and Scovill, J.P. (1979a). 2-Acetylpyridine thiosemicarbazones. 1. A new class of potential antimalarial agents. *J. Med. Chem.* 22, 855–862.
- Klayman, D.L., Scovill, J.P., Bartosevich, J.F., and Mason, C.J. (1979b). 2-Acetylpyridine thiosemicarbazones. 2. N4,N4-Disubstituted derivatives as potential antimalarial agents. *J. Med. Chem.* 22, 1367–1373.
- Krishnamoorthy, L., Cotruvo, J.A., Jr., Chan, J., Kaluarachchi, H., Muchenditsi, A., Pendyala, V.S., Jia, S., Aron, A.T., Ackerman, C.M., Wal, M.N., et al. (2016). Copper regulates cyclic-AMP-dependent lipolysis. *Nat. Chem. Biol.* 12, 586–592.
- Li, Y., and Trush, M.A. (1993). DNA damage resulting from the oxidation of hydroquinone by copper: role for a Cu(II)/Cu(I) redox cycle and reactive oxygen generation. *Carcinogenesis* 14, 1303–1311.
- Lin, H., Yu, X., Eng, O.S., Buckley, B., Kong, A.N., Bertino, J.R., Carpizo, D.R., and Gounder, M.K. (2015). A sensitive liquid chromatography-mass spectrometry bioanalytical assay for a novel anticancer candidate – ZMC1. *Biomed. Chromatogr.* 29, 1708–1714.
- Lu, J. (2010). Triethylenetetramine pharmacology and its clinical applications. *Mol. Cancer Ther.* 9, 2458–2467.
- Macomber, L., Rensing, C., and Imlay, J.A. (2007). Intracellular copper does not catalyze the formation of oxidative DNA damage in *Escherichia coli*. *J. Bacteriol.* 189, 1616–1626.
- Malmström, B.G., and Leckner, J. (1998). The chemical biology of copper. *Curr. Opin. Chem. Biol.* 2, 286–292.
- Martin, F., Linden, T., Katschinski, D.M., Oehme, F., Flamme, I., Mukhopadhyay, C.K., Eckhardt, K., Tröger, J., Barth, S., Camenisch, G., et al. (2005). Copper-dependent activation of hypoxia-inducible factor (HIF)-1: implications for ceruloplasmin regulation. *Blood* 105, 4613–4619.
- Palanimuthu, D., Shinde, S.V., Somasundaram, K., and Samuelson, A.G. (2013). In vitro and in vivo anticancer activity of copper bis(thiosemicarbazone) complexes. *J. Med. Chem.* 56, 722–734.
- Prachayasittikul, V., Prachayasittikul, S., Ruchirawat, S., and Prachayasittikul, V. (2013). 8-Hydroxyquinolines: a review of their metal chelating properties and medicinal applications. *Drug Des. Devel. Ther.* 7, 1157–1178.
- Price, K.A., Crouch, P.J., Volitakis, I., Paterson, B.M., Lim, S., Donnelly, P.S., and White, A.R. (2011). Mechanisms controlling the cellular accumulation of copper bis(thiosemicarbazone) complexes. *Inorg. Chem.* 50, 9594–9605.
- Quartararo, C.E., Reznik, E., deCarvalho, A.C., Mikkelsen, T., and Stockwell, B.R. (2015). High-throughput screening of patient-derived cultures reveals potential for precision medicine in glioblastoma. *ACS Med. Chem. Lett.* 6, 948–952.

- Ravanat, J.L., and Cadet, J. (1995). Reaction of singlet oxygen with 2'-deoxyguanosine and DNA. Isolation and Characterization of the main oxidation products. *Chem. Res. Toxicol.* 8, 379–388.
- Sartorelli, A.C., Agrawal, K.C., Tsiftoglou, A.S., and Colleen Moore, E. (1977). Characterization of the biochemical mechanism of action of  $\alpha$ -(N)-heterocyclic carboxaldehyde thiosemicarbazones. *Adv. Enzyme Regul.* 15, 117–139.
- Scrucca, L., Fop, M., Murphy, T.B., and Raftery, A.E. (2016). mclust 5: clustering, classification and density estimation using Gaussian finite mixture models. *R J.* 8, 289–317.
- Shimada, K., Skouta, R., Kaplan, A., Yang, W.S., Hayano, M., Dixon, S.J., Brown, L.M., Valenzuela, C.A., Wolpaw, A.J., and Stockwell, B.R. (2016a). Global survey of cell death mechanisms reveals metabolic regulation of ferroptosis. *Nat. Chem. Biol.* 12, 497–503.
- Shimada, K., Hayano, M., Pagano, N.C., and Stockwell, B.R. (2016b). Cell-line selectivity improves the predictive power of pharmacogenomic analyses and helps identify NADPH as biomarker for ferroptosis sensitivity. *Cell Chem. Biol.* 23, 225–235.
- Shoemaker, R.H. (2006). The NCI60 human tumour cell line anticancer drug screen. *Nat. Rev. Cancer* 6, 813–823.
- Skouta, R., Dixon, S.J., Wang, J., Dunn, D.E., Orman, M., Shimada, K., Rosenberg, P.A., Lo, D.C., Weinberg, J.M., Linkermann, A., et al. (2014). Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models. *J. Am. Chem. Soc.* 136, 4551–4556.
- Solomon, E.I., Baldwin, M.J., and Lowery, M.D. (1992). Electronic structures of active sites in copper proteins: contributions to reactivity. *Chem. Rev.* 92, 521–542.
- Soussi, T., and Wiman, K.G. (2007). Shaping genetic alterations in human cancer: the p53 mutation paradigm. *Cancer Cell* 12, 303–312.
- Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., et al. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc. Natl. Acad. Sci. USA* 102, 15545–15550.
- Trapnell, C., Pachter, L., and Salzberg, S.L. (2009). TopHat: discovering splice junctions with RNA-Seq. *Bioinformatics* 25, 1105–1111.
- Trapnell, C., Williams, B.A., Pertea, G., Mortazavi, A., Kwan, G., van Baren, M.J., Salzberg, S.L., Wold, B.J., and Pachter, L. (2010). Transcript assembly and abundance estimation from RNA-seq reveals thousands of new transcripts and switching among isoforms. *Nat. Biotechnol.* 28, 511–515.
- Uriu-Adams, J.Y., and Keen, C.L. (2005). Copper, oxidative stress, and human health. *Mol. Aspects Med.* 26, 268–298.
- Verhaegh, G.W., Parat, M.O., Richard, M.J., and Hainaut, P. (1998). Modulation of p53 protein conformation and DNA-binding activity by intracellular chelation of zinc. *Mol. Carcinog.* 21, 205–214.
- Waldron, K.J., and Robinson, N.J. (2009). How do bacterial cells ensure that metalloproteins get the correct metal? *Nat. Rev. Microbiol.* 7, 25–35.
- Williams, R.J. (2014). The natural selection of the chemical elements. *Cell. Mol. Life Sci.* 53, 816–829.
- Xu, J., Reumers, J., Couceiro, J.R., De Smet, F., Gallardo, R., Rudyak, S., Cornelis, A., Rozenski, J., Zwolinska, A., Marine, J.-C., et al. (2011). Gain of function of mutant p53 by coaggregation with multiple tumor suppressors. *Nat. Chem. Biol.* 7, 285–295.
- Yu, X., Vazquez, A., Levine, A.J., and Carpizo, D.R. (2012). Allele-specific p53 mutant reactivation. *Cancer Cell* 21, 614–625.
- Yu, X., Blanden, A.R., Narayanan, S., Jayakumar, L., Lubin, D., Augeri, D., Kimball, S.D., Loh, S.N., and Carpizo, D.R. (2014). Small molecule restoration of wildtype structure and function of mutant p53 using a novel zinc-metallo-chaperone based mechanism. *Oncotarget* 5, 8879–8892.
- Yuan, Y., Hilliard, G., Ferguson, T., and Millhorn, D.E. (2003). Cobalt inhibits the interaction between hypoxia-inducible factor- $\alpha$  and von Hippel-Lindau protein by direct binding to hypoxia-inducible factor- $\alpha$ . *J. Biol. Chem.* 278, 15911–15916.

## STAR★METHODS

### KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
<b>Antibodies</b>		
Mouse monoclonal anti- $\alpha$ tubulin (DM1A)	Santa Cruz Biotechnology	Cat# sc-32293, RRID:AB_628412
Rabbit monoclonal anti-HIF1 $\alpha$	Abcam	Cat# ab51608, RRID:AB_880418
<b>Biological Samples</b>		
Patient-derived glioblastoma cells	Henry Ford Hospital (Quartararo et al., 2015)	N/A
<b>Chemicals, Peptides, and Recombinant Proteins</b>		
NSC319726	Selleck Chemicals	Cat# S7149
7-bromo-8-hydroxyquinoline	Sigma-Aldrich	Cat# 722049
methylene blue	Sigma-Aldrich	Cat# M9140
Triethylenetetramine	Sigma-Aldrich	Cat# 90460
Bathocuproinedisulfonic acid disodium salt (BCS)	Sigma-Aldrich	Cat# B1125
Vitamin B <sub>12</sub>	Sigma-Aldrich	Cat# V6629
dimethyloxalylglycine	Sigma-Aldrich	Cat# D3695
Trolox	Sigma-Aldrich	Cat# 238813
4-hydroxy-TEMPO	Sigma-Aldrich	Cat# 176141
<i>N</i> -acetylcysteine	Sigma-Aldrich	Cat# A0737
L-Cystein	Sigma-Aldrich	Cat# C7352
Hydrogen peroxide	Sigma-Aldrich	Cat# 516813
<i>N</i> , <i>N</i> ', <i>N</i> ', <i>N</i> '- tetrakis(2- pyridinylmethyl)- 1, 2- ethanediamine	Tocris Bioscience	Cat# 4309
NaCl	Sigma-Aldrich	Cat #S7653
KCl	Sigma-Aldrich	Cat #P5405
MgCl <sub>2</sub>	Sigma-Aldrich	Cat #M8266
CaCl <sub>2</sub> •6H <sub>2</sub> O	Sigma-Aldrich	Cat #442909
MnCl <sub>2</sub>	Sigma-Aldrich	Cat #244589
FeCl <sub>2</sub> •4H <sub>2</sub> O	Sigma-Aldrich	Cat #380024
FeCl <sub>3</sub>	Sigma-Aldrich	Cat #701122
CoCl <sub>2</sub> •6H <sub>2</sub> O	Sigma-Aldrich	Cat #8661
NiCl <sub>2</sub>	Sigma-Aldrich	Cat #339350
CuCl <sub>2</sub> •2H <sub>2</sub> O	Sigma-Aldrich	Cat #C3279
ZnCl <sub>2</sub>	Sigma-Aldrich	Cat #208086
GdCl <sub>3</sub> •6H <sub>2</sub> O	Sigma-Aldrich	Cat #G7532
<b>Critical Commercial Assays</b>		
CM-H <sub>2</sub> DCFDA	Thermo Fisher Scientific	Cat# C6827
FxCycle PI/RNase staining solution	Thermo Fisher Scientific	Cat# F10797
CellTiter-Glo	Promega	Cat# G7572
PrestoBlue Cell Viability Reagent	Thermo Fisher Scientific	Cat# A13261
TruSeq RNA prep kit	Illumina	FC-122-1001
<b>Deposited Data</b>		
Normalized RNA-seq data of patient derived glioblastoma cells	This paper; Mendeley Data	<a href="https://doi.org/10.17632/2d8wzkc3v.1">https://doi.org/10.17632/2d8wzkc3v.1</a>
Metabolomic profiling data of HT-1080 cells	This paper; Mendeley Data	<a href="https://doi.org/10.17632/2d8wzkc3v.1">https://doi.org/10.17632/2d8wzkc3v.1</a>
Chemical structures of 83 compounds whose drug sensitivity profiles across NCI-60 cell lines are similar to NSC319726	This paper; Mendeley Data	<a href="https://doi.org/10.17632/2d8wzkc3v.1">https://doi.org/10.17632/2d8wzkc3v.1</a>

(Continued on next page)



## Continued

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Experimental Models: Cell Lines		
Human: HT-1080 cells	ATCC	CCL-121
Human: SH-SY5Y cells	ATCC	CRL-2266
Oligonucleotides		
SMARTpool: ON-TARGETplus HIF1A siRNA	GE Dharmacon	Cat# L-004018-00-0005
Negative Control siRNA	QIAGEN	Cat# 1027310
Software and Algorithms		
Tophat (v2.0.4)	Trapnell et al., 2009	<a href="https://ccb.jhu.edu/software/tophat/index.shtml">https://ccb.jhu.edu/software/tophat/index.shtml</a>
Cufflinks (v2.0.2)	Trapnell et al., 2010	<a href="http://cole-trapnell-lab.github.io/cufflinks/">http://cole-trapnell-lab.github.io/cufflinks/</a>
R (v3.2.1)	The Comprehensive R Archive Network	<a href="https://cran.r-project.org/">https://cran.r-project.org/</a>
flowCore package (R/Bioconductor) (v1.40.3)	Hahne et al., 2009	<a href="http://bioconductor.org/packages/release/bioc/html/flowCore.html">http://bioconductor.org/packages/release/bioc/html/flowCore.html</a>
mclust package (R) (v5.2)	Scrucca et al., 2016	<a href="https://cran.r-project.org/web/packages/mclust/index.html">https://cran.r-project.org/web/packages/mclust/index.html</a>

## CONTACT FOR REAGENT AND RESOURCE SHARING

Further information about reagents and resources used in this study, please contact Brent Stockwell ([bstockwell@columbia.edu](mailto:bstockwell@columbia.edu)).

## EXPERIMENTAL MODEL AND SUBJECT DETAILS

### Cell Lines and Tissue Culture

Collection of 13 patient-derived GBM samples were executed by Henry Ford Hospital as approved by the Institutional Review Board. The use of patient-derived GBM cell culture was executed as approved by the Institutional Review Boards of Columbia University and Henry Ford Hospital. Of 13 cells, 7 are from female patients (HF3037, HF2998, HF2885, HF2906, HF3026, HF2476, HF2790) and 6 from male (HF2381, HF2876, HF3013, HF2303, HF3177, HF2941).


Briefly, GBM cells were defrosted and grown in T-25, T-75, or T-175 tissue-culture-treated flasks as non-adhesive neurospheres in a serum-free, DMEM/F12 base media (Invitrogen #11330-057) supplemented with N-2 (Invitrogen #17502048), Bovine Serum Albumin (Sigma-Aldrich #A4919), and recombinant human EGF and FGF (PeproTech #AF-100-15 and # 100-18B, respectively). GBMs that failed to grow in suspension as neurospheres were supplemented with laminin (Sigma-Aldrich #L2020), added directly to the flask, at a concentration of 1  $\mu\text{L}/\text{cm}^2$ . Cells were cultured at 37°C, 100% humidity, and 5% CO<sub>2</sub>. Neurospheres were dissociated via Dulbecco's PBS and mechanical pipetting, while Accutase was used to detach GBMs grown on laminin. Upon dissociation, cells were counted using a Beckman Coulter Vi-Cell Cell Viability Analyzer and re-plated in the afore-described conditions.

HT-1080 cells were acquired from ATCC. Cells were submitted for authentication to ATCC (sample #STRA3235) and verified as an exact match for ATCC CCL-121 (HT-1080) on March 13<sup>th</sup> 2017. The cells grew at 37°C under 100% humidity, 5% CO<sub>2</sub>. For maintenance, HT-1080 cells were cultured in 1% non-essential amino acid and 10% fetal bovine serum containing Dulbecco modified Eagle's MEM (Gibco, #11995). One million cells were seeded per 50 mL in a T-175 flask, and cells were trypsinized and reseeded at 1:10 dilution to a new flask every two days.

SH-SY5Y cell line was obtained from ATCC and passaged a few times before use. For maintenance, cells were cultured in DMEM/F12 (ThermoFisher 10565042) supplemented with GlutaMAX, 10% heat-inactivated FBS, and Penicillin Streptomycin (Pen Strep, ThermoFisher 15070063). When reaching 90% confluency, cells were trypsinized and replated at 1:3 dilution. For differentiation, cells were plated at 40% confluency with maintenance media for 12 h, replaced with D1 media (DMEM/F12 + GlutaMAX + 5% FBS + 10  $\mu\text{M}$  retinoic acid + Pen Strep) for 5 days (fresh media change every 2 days), followed by D2 media (DMEM/F12 + GlutaMAX + 50 $\mu\text{g}/\text{mL}$  BDNF + Pen Strep) for 3 days before drug treatment. Retinoic acid and BDNF were purchased from Sigma-Aldrich (B3795-10UG and R2625-100mg, respectively).

## METHOD DETAILS

### Synthesis of NSC319726



**Scheme 1: Synthesis of NSC319726**

#### Methyl Hydrazinecarbodithioate (1)

To a cooled solution of potassium hydroxide (6.60 g, 0.1 mol, 1.0 eq) in water (8 mL) and isopropanol (6.7 mL) was added 80% hydrazine hydrate (6.26 g, 6.06 mL, 0.1 mol, 1.0 eq). Ice-cooled carbon disulfide (7.61 g, 6.04 mL, 0.1 mol, 1.0 eq) was added dropwise to the stirred solution over 90 min, while keeping the temperature of the reaction mixture below 10°C. The bright yellow mixture was stirred for an additional 1 h, after which ice-cooled methyl iodide (14.2 g, 6.23 mL, 0.1 mol, 1.0 eq) was added dropwise over a 2 h period and the mixture was allowed to stir overnight while slowly warming to room temperature. The white precipitate was collected by filtration and washed with ice-cold water. The crude product was recrystallized from dichloromethane to give methyl hydrazinecarbodithioate (1): 2.8 g, 23% yield. The spectroscopic data matched those reported in the literature (Klayman et al., 1979a).

#### Methyl 2-(1-(pyridin-2-yl)ethylidene)hydrazine-1-Carbodithioate (2)

Methyl hydrazinecarbodithioate (1, 2.8 g, 22.95 mmol) was dissolved in isopropanol (7 mL) and 2-acetylpyridine was added (2.79 g, 2.59 mL, 23.07 mmol, 1.005 eq). The reaction mixture turned yellow followed by precipitation of a yellow solid. The reaction mixture was stirred for an additional 2 h and cooled overnight. The precipitate was collected by filtration, washed with isopropanol and air-dried to yield methyl 2-(1-(pyridin-2-yl)ethylidene)hydrazine-1-carbodithioate (2): 4.72 g, 91% yield as a 63:37 mixture of *E/Z*-isomers. The spectroscopic data matched those reported in the literature (Klayman et al., 1979a).

(*E*)-*N'*-(1-(pyridin-2-yl)ethylidene)azetidine-1-carbothiohydrazide (NSC319726) (Klayman et al., 1979b):

Methyl 2-(1-(pyridin-2-yl)ethylidene)hydrazine-1-carbodithioate (2, 2.25 g, 10 mmol, 1.0 eq) was suspended in methanol (25 mL) and azetidine (0.57 g, 674  $\mu$ L, 10 mmol, 1.0 eq) was added and the mixture was stirred at 50°C for 6 h. The solid dissolved and after 20 min a white solid precipitated. After cooling to room temperature the solid was collected by filtration to give the product as a fine white powder, NSC319726: 1.81 g, 77% yield.

<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  10.19 (s, 1H), 8.59 (dt, *J* = 4.9, 1.2 Hz, 1H), 7.93 (d, *J* = 8.0 Hz, 1H), 7.82 (td, *J* = 7.7, 1.8 Hz, 1H), 7.38 (ddd, *J* = 7.4, 4.8, 1.2 Hz, 1H), 4.58 (bs, 2H), 4.13 (bs, 2H), 2.35 (s, 3H), 2.25 (p, *J* = 7.8 Hz, 2H) ppm.

<sup>13</sup>C NMR (100 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  175.8, 155.0, 148.6, 148.5, 136.7, 123.8, 119.8, 56.6, 53.1, 16.0, 11.6 ppm.

HRMS (ESI+, *m/z*): calcd for C<sub>11</sub>H<sub>15</sub>N<sub>4</sub>S [M+H]<sup>+</sup>: 235.1017, found: 235.1020.

#### Cell Viability Assay

When cellular viability assays were performed in 384-well plates (Corning #3712), we often treated cells with two components. A compound tested in a 2-fold dilution series (denoted as *L* as they are often lethal compounds), and a modulator tested at a single concentration (denoted as *M* here). *M* may interfere with cellular signaling responding to the stimuli *L* and consequently it may affect the phenotype. *M* was already treated to the cellular suspension before seeding cells (e.g., when *M* is a compound, it was added to the cell suspension just before seeding the cells to plates; when siRNAs, cells were first transfected as described in the following section, and in two days transfected cells expressing the siRNAs were reseeded in 384 well plates). 1,000 (HT-1080) or 2,000 (GBMs) cells treated with *M* were seeded per 36  $\mu$ L in each well of 384 well plates (Corning, #3712). Compounds examined in assays were first dissolved in appropriate solutions (dimethylsulfoxide, ethanol, or culture media, depending on the compounds' solubility), and then diluted to make 10x concentrations of the tested concentrations in the culture media. 4  $\mu$ L of the 10x solutions were added to each well, which results in treating cells with 1x concentration of the compounds. After cells were incubated with the compounds for 48 h, 10  $\mu$ L per well of 50% Presto Blue (Thermo Fisher Scientific) in culture media was added to each plate, the plates were further incubated for eight hours, and the fluorescence (ex/em: 530/590) was measured using a Victor plate reader (Perkin Elmer). The raw fluorescence acquired from the plate reader was normalized using the following equation:  $V_{L|M} = (I_{M,L} - I_0) / (I_M - I_0)$ , where  $I_{M,L}$ ,  $I_M$ , and  $I_0$  correspond to fluorescence intensity from wells containing cells treated with *M* and *L*, wells containing cells treated with *M* only, and wells containing media, *M*, and *L* (but no cells), respectively. The resulting value ( $V_{L|M}$ ) is the normalized

viability. Note that  $V_{L|M} = 0$  and 1 indicate that  $L$  completely kills the cells or that  $L$  does not induce any growth inhibitory effect, respectively. When only a lethal compound was treated to cells in dilution series, we still use this equation but in this case  $M$  is the vehicle control. The assays were done in biological triplicates; a representative single experiment was chosen to show dose-concentration curves for viability. In a plot, points are the mean of normalized viability tested in technical triplicates.

### Sequencing of *TP53* Gene of 13 GBM Primary Cells

*TP53* primers were designed using the Consensus CDS (CCDS) available on the NCBI website (CCDS11118.1), with forward primer TGAAGCTCCCAGAATGCCAG and reverse primer TCTCGGAACATCTCGAAGCG. The total sequence covered 846 bp, including both primers. The forward primer extended from nucleotide 183 to 202, with the reverse primer extending from nucleotide 1009 to 1028.

Upon neurosphere dissociation or laminin detachment, RNA was collected from untreated GBM cells with a Qiagen QIAshredder (#79656) and RNeasy Mini Kit (#74106) as per the protocol provided with the kit, analyzed for quality via Nanodrop Lite spectrophotometer, and cDNA was generated from each sample through PCR reaction with the aforementioned *TP53* primers.

cDNA samples were sent to GENEWIZ for sequencing, and GBM *TP53* sequences were returned aligned with the actual, expected *TP53* sequence. Upon visual inspection, mismatched pairs of nucleotides were identified, highlighted, and matched to the translated amino acid they code for.

### Screening for Lethal Compounds in 13 GBM Primary Cells

Lethal compounds were tested within GBM patient models as per the high-throughput screening protocol established in Quartararo *et al.* (Quartararo *et al.*, 2015). In brief, immediately upon detachment of adhesive cells or dissociation of neurospheres, GBMs were seeded in 384-well, white, opaque, tissue-culture-treated plates (PerkinElmer, #6007688) at a density of 1,000 cells per well, with 26  $\mu$ L of growth media in each well. 24 h later, inhibitors were added in a 17-point, two-fold dilution series. The final concentration range was 0.8 nM to 50  $\mu$ M. 72 h post inhibitor addition, a one-to-one mixture of DMEM/F12 and CellTiter-Glo (CTG) was added, and luminescence was quantified with a PerkinElmer Victor X5 plate reader. A Biomek FX liquid handling system was used to seed cells, add inhibitors, and add the DMEM/F12:CTG luminescence mix, with cell-seeded plates maintained in a 37°C, 100% humidity, 5% CO<sub>2</sub> environment during incubation and post inhibitor addition.

Percent viability was calculated using growth media only wells as 0% viable, and 0.5% DMSO treated cells as 100% viable. GraphPad Prism 6.0e was used to calculate the EC<sub>50</sub> values for each compound with four-parameter Hill equation, or “log(inhibitor) vs. response- Variable slope (four parameters)”.

### Screening for a Responsible Metal in NSC319726-Induced Cell Death

1,000 HT-1080 cells/32  $\mu$ L per well were seeded in a 384-well plate. The cells were grown overnight under 5% CO<sub>2</sub> at 37°C. On the next day, 4  $\mu$ L/well of 10x metal chloride and 4  $\mu$ L/well 310 nM NSC319726 with or without 1 mM Co(II) were concomitantly added. When the solutions were added, cells were treated with 31 nM NSC319726, with or without 100  $\mu$ M Co(II) and with 2-fold 12-point dilution series of metal chloride with the highest concentration of 100  $\mu$ M. The cells were incubated for 48 h followed by addition of Presto Blue, incubation for 5 h and subsequent fluorescence measurement. Note that metal salts were tested in a dilution series and NSC319726 was tested at a fixed concentration. Therefore, as described in ‘Cell Viability Assay’ section above, the normalized viability of one corresponds to the viability of cells treated with DMSO, NSC319726, DMSO/Co(II), or NSC319726/Co(II), equivalent to the condition of interest, but only without metals.

### Inductively Coupled Plasma-Mass Spectrometry (ICP-MS) for Metal Quantification

Cells were plated in 6-well plates and cultured for one day. The vehicle or compounds were added to the cells the following day and incubated for specified times. NSC319726, 7Br8HQ and MB were added for 24 h. Cobalt chloride was added either alone or in combination with NSC319726 for 24 h. The plates were then washed 2 times with PBS containing 1 mM EDTA and 2 times with PBS alone. After the addition of 215  $\mu$ L concentrated nitric acid (BDH Aristar Ultra), the plates were sealed with parafilm and incubated overnight. The samples (150  $\mu$ L) were then diluted in 2 mL 2% nitric acid (ultrapure nitric acid diluted in MilliQ water) and analyzed on a Thermo Fisher iCAP Qc ICP mass spectrometer in Kinetic Energy Discrimination (KED) mode against a calibration curve of known copper, zinc, iron, cobalt and phosphorus concentrations, with gallium (20  $\mu$ g/L, Inorganic Ventures) as an internal standard. Each experiment was carried out thrice and each condition was repeated in at least triplicate.

### RNA-Seq Experiment

Sample collection. Poly-A pull-down was performed to enrich mRNAs from total RNA samples (200 ng - 1  $\mu$ g per sample, RIN>8 required) and mRNAs were proceeded to library preparation by using Illumina TruSeq RNA prep kit. Libraries were then sequenced using Illumina HiSeq2000 at Columbia Genome Center.

Samples were multiplexed in each lane, which yields targeted number of single-end/paired-end 100bp reads for each sample, as a fraction of 180 million reads for the whole lane. The data analysis of the acquired sequencing was performed as described later in Quantification and Statistical Analysis.

### HIF-1 $\alpha$ Knockdown

Gene knockdown was performed using siRNA reverse transfection. Non-targeting control or HIF-1 $\alpha$ -targeting siRNAs (GE Dharmacon) were dissolved in RNase-free water to make 10  $\mu$ M stocks. 6  $\mu$ L of siRNA solution and 15  $\mu$ L of Lipofectamine RNAiMAX (Thermo Fisher Scientific) were added to 500  $\mu$ L OptiMEM media (Thermo Fisher) in each eppendorf tube, and placed on a well in 6-well plate. Three wells per each siRNA were prepared. After the plates were incubated for 15 minutes at 37°C, 120,000 HT-1080 cells per 1.5 mL in each well (*i.e.*, 80,000 cells per mL) were seeded. Cells were incubated to allow knockdown proceeded for 48 h. Cells were trypsinized and reseeded for further western blotting and viability assays.

### Hypoxia Induction

In order to perform assays at 1.5% O<sub>2</sub>, a H35 HypOxystation (HypOxygen) was used. Upon seeding cells, plates designated for hypoxia testing were manually transferred into the station, and inhibitors were added 24 h later by hand with the plates still inside the Hypoxia chamber. For cell viability assay, 48 h (HT-1080) or 72 h (GBM) post inhibitor addition, plates were removed and DMEM/F12:CTG was added as described above.

### Western Blotting

300,000 HT-1080 cells were seeded per well in a 6-well plate. The cells were treated with 100  $\mu$ M Co(II) chloride, 100  $\mu$ M DMOG, or media. The plates were grown under either hypoxia (1.5% O<sub>2</sub>) or normoxia (21% O<sub>2</sub>) and under 5% CO<sub>2</sub> at 37°C for 24 h. As soon as the plates were taken out of the incubator or hypoxia chamber, they were harvested at normoxia and ambient temperature. Procedure for cell lysis, SDS-PAGE, and western blotting, was described previously (Dixon et al., 2012). Antibodies used were: anti-human  $\alpha$ -tubulin (Santa Cruz Biotechnology, sc-32293, 1:10,000 dilution), and anti-human HIF-1 $\alpha$  (Abcam, ab51608).

### ROS Detection in Cell Culture

HT-1080 cells were trypsinized and diluted to a final density of 100,000 per mL. The cells were then incubated with 1  $\mu$ M of CM-H<sub>2</sub>DCFDA for 30 min, spun down at 660  $\times$  g for 3 mins, and the supernatant was replaced with fresh media containing lethal compounds and/or Cu(II). Then, the cells were incubated for 30 mins, spun down, and the supernatant was replaced with fresh media. Fluorescence of samples was measured at the FL1-H channel using the Accuri C6 flow cytometer (BD Biosciences). Flow cytometry data were analyzed and visualized using flowCore package (Hahne et al., 2009) and R.

### ROS Detection in Cell Free System

Phosphate Buffered Saline (PBS), L-Cysteine (Sigma-Aldrich, #C7352), and H<sub>2</sub>O<sub>2</sub> (Sigma-Aldrich, #516813, 50 wt. % in H<sub>2</sub>O) were used to generate a master mix (MM) at a pH of 7.4. A clear 96 well plate (Sigma-Aldrich, #CLS3596) had the following conditions added per row, with a technical triplicate of wells for each condition: PBS only, H<sub>2</sub>DCFDA only, MM only, MM with CuCl<sub>2</sub>, MM with NSC319726, and MM with both CuCl<sub>2</sub> and NSC319726. The final volume per well was 200  $\mu$ L, with the following concentrations of components per relevant well: H<sub>2</sub>DCFDA at 5  $\mu$ M, Cysteine at 100  $\mu$ M, H<sub>2</sub>O<sub>2</sub> at 100  $\mu$ M, NSC319726 at 10  $\mu$ M, and CuCl<sub>2</sub> at 10  $\mu$ M. The plate was incubated at 37°C for minutes and read using a Victor X5 plate reader (ex/em: 485/535). The experiment was done in biological duplicates. Data was analyzed using Microsoft Excel.

### Cell Cycle Assay

300,000 HT-1080 cells per well were plated in 6-well plates and treated with 1  $\mu$ M NSC319726, 50  $\mu$ M 7Br8HQ, or 50  $\mu$ M MB for 12 h. The cells were trypsinized and spun down at 700 rcf. The pellets were triturated and fixed with ice-cold 70% ethanol for 30 mins. The cells were then spun down at 1,500  $\times$  g. After a PBS wash, the cells were incubated in 500  $\mu$ L FxCycle PI/RNase staining solution at room temperature for 30 mins while protected from light. Cells were immediately analyzed on the Accuri C6 flow cytometer (BD Biosciences), and the fluorescence intensity on the FL2-A or FL3-A channel was monitored. Flow cytometry data were analyzed and visualized using flowCore package and R.

### Metabolomic Profiling

HT-1080 cells were seeded into 10 million cells per T-175 flask in four flasks. Immediately, two flasks were treated with 0.1% DMSO and two with 5  $\mu$ M NSC319726 and incubated for six hours. The cells were trypsinized and collected into 15 mL conical tubes. 500  $\mu$ L from each tube was saved for cell counting using ViCell (Beckman Coulter), and the rest of the tubes were spun down at 1,500 rpm for 5 mins. Pellets were washed gently with 5mL PBS. 500  $\mu$ L PBS was added to the pellets, triturated, and transferred to cryovials. The tubes were spun down at 1,500 rpm for 5mins, and the supernatant was removed. The pellet was flash frozen in a dry ice-isopropanol bath and stored at -80°C. Sample collection was performed in biological quadruplicates. After the last sample collection, the samples were shipped in dry ice to Metabolon for further sample preparation. At Metabolon, 505 metabolites from the samples were identified and quantified using LC/MS and GC/MS as described previously (Skouta et al., 2014).

### Neurotoxicity Assays

For 96-well plate assays, SH-SY5Y cells were plated at 5K/well. For undifferentiated condition, cells were treated with drugs 24 h after seeding, and for differentiated condition, cells were treated 3 days after switching to D2 media. In both conditions, four drugs



were treated at 9-point 2-fold dilution series and cells were incubated for 48 h before viability was measured using CellTiter-Glo (Promega, G7572). Images were taken by IncuCyte (EssenBioscience) at 10X after drug treatment for 48 h.

## QUANTIFICATION AND STATISTICAL ANALYSIS

### Pharmacogenomic Analysis of the NCI-60 Data

The NCI-60 data analysis was done as described previously (Shimada et al., 2016b). Briefly, 2,565 cell-line-selective lethal compounds were clustered into 18 groups based on growth inhibition ( $GI_{50}$ ) profiles in the NCI-60 panel using Gaussian finite mixture model and hierarchical clustering. The former was performed using mclust R package (Scrucca et al., 2016). Each cluster represents distinct mechanisms of action. The Spearman correlation between each compound cluster's  $GI_{50}$  profile and each gene's expression across the panel was computed. This correlation matrix (18 compound clusters x 11,642 genes) was used for pathway enrichment analysis (see below).

### Processing of Raw Sequences from RNA-Seq

Raw sequences from RNA-seq of GBM cells were acquired as described above. RTA (Illumina) was used for base calling and bcl2fastq (version 1.8.4) for converting BCL to fastq format, coupled with adaptor trimming. The reads were mapped to a reference genome (Human: NCBI/build37.2) using Tophat (version 2.0.4) with 4 mismatches and 10 maximum multiple hits (Trapnell et al., 2009). The relative abundance (aka expression level) of genes and splice isoforms were estimated using cufflinks (version 2.0.2) with default settings (Trapnell et al., 2010).

### Analysis of RNA-Seq Data

Normalized data (FPKM values) of the eight samples (HF3037 and HF2941 cells treated with DMSO or NSC319726, each with biological duplicate) were provided by Columbia University Genome Center. A pseudo-count one was added to all the FPKM values, which were then log-transformed, i.e.,  $x_g = \log_{10}(n_g + 1)$ . For each cell line, the expression change of each gene  $g$  is computed by averaging the log-expressions between the duplicates and subtract the expressions induced by NSC319726 from the ones induced by DMSO. These expression profiles were then examined for pathway enrichment analysis as described above to identify pathways (i.e., gene sets) that were up- or down-regulated upon NSC319726 treatment.

### Pathway Enrichment Analysis

Pathway enrichment analysis is the core of our transcriptome analysis to understand the mechanism of lethality of NSC319726. From the normalized NCI-60 and GBM data, we looked for pathways overrepresenting positively or negatively correlated genes in the NCI-60 data and up- or down-regulated genes upon NSC319726 treatment in the GBM transcriptome (Figures 4A and S2). We utilized the Broad Institute's Molecular Signature Database (MSigDB) as collection of pathways (Subramanian et al., 2005). In the first analysis (Figure S2), we limited our analysis to Gene Ontology, Canonical pathways, BIOCARTA, KEGG, REACTOME, and 'Hallmarks' in MSigDB. In the second analysis (Figure S4), we used 3,400 'chemical and genetic perturbation' gene sets in MSigDB that are collections of up- and down-regulated genes from previously published experiments; we looked for experimental conditions that induce similar gene expression changes to our NSC319726 treatment in GBM cells.

To compute the significance of overrepresentation of a pathway, we developed a method using one-sided Fisher's exact test. First, genes were sorted based on correlation coefficients for the NCI-60 data, or log fold changes for the GBM RNA-seq data (NSC319726 treatment over vehicle treatment). Second, we selected top and bottom  $n\%$  of sorted genes ( $n=5, 10, 15, \dots, 95$ ), which gives 38 ways of gene selection. Third, we assessed the significance of overrepresentation of a pathway for each of these 38 selections. Finally,  $p$ -value that gives the lowest of the 38 selections was set as the significance of the enrichment of this pathway. When the lowest  $p$ -value was given by "top" or "bottom" genes, the pathway was considered up- or down-regulated, respectively. The  $p$ -values were further converted to signed log  $p$ -values, namely  $\log_{10}(p\text{-value})$  multiplied by 1 or -1 when the pathway was up- or down-regulated, respectively; large positive or negative signed log  $p$ -values indicate significant up- or down-regulation.

To further assess the mechanism of action of the compound cluster containing NSC319726 and other thiosemicarbazones (we call it cluster  $g$  here), we looked for pathways that are not only significantly but also exclusively associated with the cluster here. To find such exclusive association, we calculated pathways' "specificity" for the cluster  $g$  (Shimada et al., 2016b). Specificity of a pathway in a compound cluster across multiple clusters becomes positive only when the pathway is most significantly associated with the cluster  $g$  in the same direction (up- or down-regulated) across the 18 clusters. Specificity ( $Sp$ ) is mathematically defined as  $Sp = \min(\Delta slp_g) \cdot \text{sign}(slp_g)$ , where  $\Delta slp_g$  is a vector containing difference of signed log  $p$ -values ( $slp$ ) between cluster  $g$  and the other 17 clusters,  $\min()$  returns a minimum value of the vector, and  $\text{sign}()$  is a sign function.

### Predicting Functionally Relevant Pathways

As summarized in Figure S2A, we suspected that pathways i) enriched in genes positively correlated with drug-sensitivity profiles (i.e., genes more expressed in resistant cells) from NCI-60 analysis and ii) whose transcriptional activity is upregulated upon NSC319726 treatment are more likely to be involved in protecting cells from the compound, while pathways i) enriched in negatively correlated genes as well as ii) whose transcriptional activity is downregulated upon the compound treatment are more likely to sensitize cells to the lethal stimuli. In both NCI60 and GBM transcriptome analyses, we set specificity of  $\pm 5$  and significance of  $\pm 10$  as

thresholds for calling them specific and significant, respectively (Figures S2B and S2C), and we eventually found two pathways (HALLMARK\_TNFA\_SIGNALING\_VIA\_NFKB and HALLMARK\_HYPOXIA) that likely support the cells to survive from the NSC319726's lethality.

#### DATA AND SOFTWARE AVAILABILITY

Normalized RNA-seq data of patient-derived glioblastoma cells, normalized metabolomic profiling data of HT-1080 cells, and chemical structures of 83 compounds whose drug sensitivity profiles across NCI-60 cell lines are similar to NSC319726, are available at Mendeley Data (<https://doi.org/10.17632/2d8wzkc3v.1>).